AUSTRALIAN PRODUCT INFORMATION – SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (ELASOMERAN/DAVESOMERAN) COVID-19 VACCINE
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 Vaccine has provisional approval as a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Product Information
Consumer Medicine Information
SPIKEVAX BIVALENT ORIGINAL/OMICRON (ELASOMERAN/IMELASOMERAN) COVID-19 VACCINE
SPIKEVAX BIVALENT ORIGINAL/OMICRON (elasomeran/imelasomeran) COVID-19 Vaccine has provisional approval for the indication below:
As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.
Product Information
Consumer Medicine Information
Spikevax (previously COVID‑19 Vaccine Moderna)
SPIKEVAX (elasomeran) COVID-19 Vaccine has provisional approval for the indication below:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months of age to <6 years of age.
SPIKEVAX (elasomeran) COVID-19 Vaccine is indicated for:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 years of age and older.
Product Information
Consumer Medicine Information
Tools
Report Adverse Events
Report any adverse events to Moderna via the Adverse Event Intake Portal or by calling 1800 344 018.
Contact Moderna
8am-5pm AEST Mon-Fri
APACMedInfo@modernatx.com